A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07136077
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Adjuvant Chemotherapy
  • Colorectal Cancer
  • Fruquintinib
  • Minimal Residual Disease
  • Tislelizumab
  • ctDNA

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tislelizumab — DRUG
    Given by IV
  • Fruquintinib — DRUG
    Give by PO

Study Details

To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).

Key Dates

Start date
Sep 18, 2025
Status verified
May 2026
Primary completion
Dec 1, 2027
Completion
Apr 1, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase II: Treatment with Fruquintinib and Tislelizumab
    Treatment with Fruquintinib and Tislelizumab

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Arvind Dasari, MD
[email protected]
713-792-2828
Arvind Dasari, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies